Home  >  Products  >  SPG21 (spastic paraplegia 21 (autosomal recessive, Mast syndrome) ) Blocking Peptide (the C terminal of SPG21)(100ug)
SPG21 (spastic paraplegia 21 (autosomal recessive, Mast syndrome) ) Blocking Peptide (the C terminal of SPG21)(100ug)

SPG21 (spastic paraplegia 21 (autosomal recessive, Mast syndrome) ) Blocking Peptide (the C terminal of SPG21)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-SPG21 Antibody (ARP65714_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP65714
Size: 100ug
Weight: 35kDa
Gene: 51324
Format: Lyophilized powder
Target: The protein encoded by this gene was identified by a two-hybrid screen using CD4 as the bait. It binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. At least three different transcript variants encoding two different isoforms have been found for this gene.
Alternative names: ACP33; BM-019; GL010; MASPARDIN; MAST
See Full Product Listings >